Kuntai Capsule plus Hormone Therapy vs. Hormone Therapy Alone in Patients with Premature Ovarian Failure: A Systematic Review and Meta-Analysis

Table 1

Basic details of included studies.

Included study	Sample size		Adverse reaction report	Interventions		Duration of treatment; (month)	Outcome; index	Jadad; score
	Trial group	Control group		Trial group	Control group
X.H. Zhou (2018)	41	41	Yes	Estrogen; + Medroxyprogesterone; + KTC	Estrogen; + Medroxyprogesterone	3	A+B+C	2
Y.Y. Wu; et al (2016)	75	75	NR	Climen (estradiolo valerato/cyproterone acetate); + KTC	Climen (estradiolo valerato/cyproterone acetate)	6	A+B	2
S.Q. Kang (2018)	39	39	Yes	Climen (estradiolo valerato/cyproterone acetate)/progesterone; + KTC	Climen (estradiolo valerato/cyproterone acetate)/progesterone	6	A+B	2
S.Y. Zeng; et al (2014)	39	39	NR	Progynova (estradiolo valerato)/progesterone; + KTC	Progynova (estradiolo valerato)/progesterone	3	A+B	1
H.P. Li; et al (2018)	39	39	NR	Progynova (estradiolo valerato)/progesterone; + KTC	Progynova (estradiolo valerato)/progesterone	3 weeks	A+B+D	2
R.Z. Li (2014)	55	55	Yes	Progynova (estradiolo valerato) + KTC	Progynova (estradiolo valerato)	1	A+B	2
X.Q. Yang; (2017)	63	63	Yes	Climen (estradiolo valerato/cyproterone acetate); + KTC	Climen (estradiolo valerato/cyproterone acetate)	6	A+B	2
S.R. Pan; et al (2015)	53	52	Yes	Diethylstilbestrol; /progesterone; + KTC	Diethylstilbestrol; /progesterone	6	A+B	2
H.F. Yuan; et al (2018)	41	40	NR	Climen (estradiolo valerato/cyproterone acetate); + KTC	Climen (estradiolo valerato/cyproterone acetate)	3	A+B+E+F	1
Q.H. Deng e. al (2017)	50	50	NR	Yasmin (ethinylestradiol/drospirenone) + KTC	Yasmin (ethinylestradiol/drospirenone)	3	A+B+C +D+ E+G+H	1
J. Guo (2017)	54	54	NR	Progynova (estradiolo valerato) + KTC	Progynova (estradiolo valerato)	50 days	A+B+C	1
X.L. Gao; (2017)	41	41	NR	Progynova (estradiolo valerato)/progesterone; + KTC	Progynova (estradiolo valerato)/progesterone	3	A+B	1

Note: A: total effective treatment rate; B: luteinizing hormone (LH) + follicle-stimulating hormone (FSH) + estrogen (E2) levels; C: lipid index levels (triglyceride [TG], total cholesterol [TC], low-density lipoprotein-cholesterol [LDL-C], high-density lipoprotein-cholesterol [HDL-C]); D: ovarian resistance index (RI), perfusion index (PI), and peak systolic velocity (PSV); E: antral follicle count (AFC); F: anti-Müllerian hormone (AMH); G: Kupperman score; H: mean ovarian diameter (MOD) in the plane containing the longest axis of the ovary; NR: no report. In each study, all the baseline characteristics were equally distributed between the trial and control groups.